#United States #Richmond #Neurodegenerative Diseases #BRAINBox Solutions #concussion diagnostics

BRAINBox Solutions Expands Patent Portfolio

BRAINBox Solutions, a prominent player in the field of brain injury diagnostics, has recently expanded its patent portfolio to further enhance its capabilities in the diagnosis and prognosis of concussions and related neurodegenerative conditions. An announcement made on April 16, 2026, revealed that the U.S. Patent and Trademark Office has issued three additional patents to the company, reinforcing its intellectual property rights and technological advancements.

Expanding Capabilities for Concussion Diagnosis

The three new patents are pivotal for BRAINBox, adding significant depth to its diagnostic tools focused on mild traumatic brain injuries, commonly known as concussions. According to CEO Donna Edmonds, these patents bolster the company’s position in the market by covering specific biomarker combinations necessary for the detection and treatment of neurodegenerative diseases and traumatic brain injuries. BRAINBox now holds 22 patents globally, with 19 existing in the United States alone, demonstrating a robust commitment to innovation in this critical healthcare sector.

The Patents and Their Significance:

• - Methods and Compositions for Diagnosing Brain Injury or Neurodegeneration (U.S. Patent No. 12,560,619): This patent extends the coverage of the biomarker β-synuclein, crucial for diagnosing conditions such as Parkinson’s and Alzheimer’s disease, alongside general traumatic brain injuries.
• - Biomarker Levels and Neuroimaging for Detecting, Monitoring, and Treating Brain Injury or Trauma (U.S. Patent No. 12,461,112): This patent focuses on key neurological biomarkers, enabling medical professionals to identify the need for imaging studies to detect fiber tract injuries in the brain effectively.
• - Protein Biomarker Indicators of Neurological Injury and/or Disease (U.S. Patent No. 11,988,676): This patent addresses the use of vital vascular and synaptic biomarkers, including von Willebrand Factor and astrotactin-2, to diagnose TBI and other neurological conditions. It also complements a pending application that covers an impressive collection of 79 additional novel biomarkers found in biofluids.

BRAINBox's Vision and Future Developments

As a pioneer in AI-enabled diagnostics for mild traumatic brain injuries, BRAINBox Solutions is committed to establishing a clinical best-practice standard. Their innovative diagnostic approaches include utilizing a panel of proprietary, patented blood biomarkers that can provide quick assessments using point-of-care instruments, or standard laboratory systems. In addition to biomarker evaluations, neurocognitive tests are integral to the process, allowing clinicians to obtain comprehensive insights into the severity of injuries and post-concussive symptoms.

The company is helmed by experienced physician and scientific leaders dedicated to pushing the boundaries of brain injury diagnostics and treatment. As BRAINBox continues to advance its research and development initiatives, the expectation is that these patents will play a crucial role in their ongoing efforts to standardize concussion evaluations and ensure effective management strategies moving forward.

To learn more about BRAINBox Solutions and their cutting-edge technological advancements, visit www.brainboxinc.com.

Conclusion

BRAINBox Solutions' latest patent advancements are expected to significantly contribute to the understanding and treatment of concussions and neurodegenerative diseases. As the healthcare landscape evolves, innovations like these are pivotal in equipping practitioners with the essential tools for patient care. The company's strategic expansion in patent acquisitions demonstrates not only its commitment to improving diagnostic technologies but also a transformative vision for the future of brain health management.